<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519386</url>
  </required_header>
  <id_info>
    <org_study_id>GC-010</org_study_id>
    <nct_id>NCT03519386</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%</brief_title>
  <official_title>Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III study to compare the safety and efficacy of intraocular implants containing&#xD;
      travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5%&#xD;
      (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma&#xD;
      (OAG) or ocular hypertension (OHT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-masked, active-controlled, parallel-group,&#xD;
      multi-center trial comparing the efficacy and safety of the Model G2TR 063 Travoprost&#xD;
      Intraocular Implant and the Model G2TR-125 Travoprost Intraocular Implant to topical timolol&#xD;
      in subjects with OAG or OHT. The staff who record key efficacy measures and the study&#xD;
      subjects will remain masked to study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP (Control Group vs. Each Implant Group) through 3 months postoperative</measure>
    <time_frame>3 months</time_frame>
    <description>Difference in mean diurnal IOP, between each test group and the control group, for IOP measurements through the Month 3 follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean IOP (Control Group vs. Each Implant Group) through 12 months postoperative</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in mean IOP, between each test group and the control group, for IOP measurements through the Month 12 follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Implant Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G2TR intraocular implant containing travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Implant Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G2TR intraocular implant containing travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sham surgery + active-comparator eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>G2TR intraocular implant containing travoprost</intervention_name>
    <description>Provided in Arm/Group descriptions.</description>
    <arm_group_label>Implant Group 1</arm_group_label>
    <arm_group_label>Implant Group 2</arm_group_label>
    <other_name>Implant Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham surgery + active-comparator eye drops</intervention_name>
    <description>Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Control Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with open-angle glaucoma or ocular hypertension.&#xD;
&#xD;
          -  C/D ratio â‰¤ 0.8&#xD;
&#xD;
          -  Zero to three preoperative ocular hypotensive medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active corneal inflammation or edema.&#xD;
&#xD;
          -  Retinal disorders not associated with glaucoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry Stephens, O.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Glaukos Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

